Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
LP Jordheim, D Durantel, F Zoulim… - Nature reviews Drug …, 2013 - nature.com
Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …
cornerstones of treatment for patients with cancer or viral infections. The approval of several …
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma
…, T André, C Dumontet, CE Cass, LP Jordheim… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: Patients who undergo surgery for pancreatic ductal adenocarcinoma
(PDAC) frequently receive adjuvant gemcitabine chemotherapy. Key determinants of …
(PDAC) frequently receive adjuvant gemcitabine chemotherapy. Key determinants of …
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
LP Jordheim, P Sève, O Trédan, C Dumontet - The lancet oncology, 2011 - thelancet.com
The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of
cell proliferation, cell migration, tumour and metastasis development, and the synthesis of …
cell proliferation, cell migration, tumour and metastasis development, and the synthesis of …
[HTML][HTML] The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent
…, D Mathe, A Tourette, L Serre, LP Jordheim… - Frontiers in …, 2018 - frontiersin.org
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors
(ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine …
(ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine …
Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells
LP Jordheim, KH Barakat, L Heinrich-Balard… - Molecular …, 2013 - ASPET
The benefit of cancer chemotherapy based on alkylating agents is limited because of the
action of DNA repair enzymes, which mitigate the damage induced by these agents. The …
action of DNA repair enzymes, which mitigate the damage induced by these agents. The …
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues
LP Jordheim, C Dumontet - Biochimica et Biophysica Acta (BBA)-Reviews …, 2007 - Elsevier
Cytotoxic deoxynucleoside analogues are widely used in the treatment of haematological
malignancies and solid tumours. Their metabolism and mechanisms of action are relatively …
malignancies and solid tumours. Their metabolism and mechanisms of action are relatively …
[HTML][HTML] Hybrid core-shell particles for mRNA systemic delivery
mRNA based infectious disease vaccines have opened the venue for development of novel
nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are …
nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are …
Nano-encapsulation of Vitamin D3 Active Metabolites for Application in Chemotherapy: Formulation Study and in Vitro Evaluation
Purpose Calcitriol (1,25-dihydroxyvitamin D 3 ), the active metabolite of vitamin D 3 , is a
potential anticancer agent but with high risk of hypercalcemia which limits the achievement of …
potential anticancer agent but with high risk of hypercalcemia which limits the achievement of …
Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry
S Cohen, M Megherbi, LP Jordheim, I Lefebvre… - … of chromatography B, 2009 - Elsevier
In this study, we developed a new method for the simultaneous determination of eight
endogenous ribonucleoside triphosphates and deoxyribonucleoside triphosphates based on a …
endogenous ribonucleoside triphosphates and deoxyribonucleoside triphosphates based on a …
Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug
LP Jordheim, E Cros, MH Gouy, CM Galmarini… - Clinical Cancer …, 2004 - AACR
Resistance to cytotoxic nucleoside analogues is a major problem in cancer treatment. The
cellular mechanisms involved in this phenomenon have been studied for several years, and …
cellular mechanisms involved in this phenomenon have been studied for several years, and …